levosulpiride and Abnormalities--Drug-Induced

This study aimed to evaluate pregnancy outcomes of women who were inadvertently exposed to levosulpiride in early pregnancy. All 162 consecutive singleton pregnant women counselled through the Korean Motherisk Program, Cheil General Hospital, between April 2001 and April 2014, on teratogenic risk after inadvertent exposure to levosulpiride in early pregnancy were enrolled in this study. The women were exposed to levosulpiride at median 4.8 gestational weeks. The rate of miscarriage was not significantly different between groups (9.2% in those exposed and 5.5% in the non-exposed; p = .084). The rate of major malformations was not significantly different between exposed (2.7%) and non-exposed pregnancies (4.4%) (p = .481). All other pregnancy outcomes between the two groups were comparable (p > .05). Our data suggest that levosulpiride causes no significant adverse effects on pregnancy outcomes and therefore may be not a major teratogen.

Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Cohort Studies; Congenital Abnormalities; Female; Gestational Age; Humans; Maternal Exposure; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Prospective Studies; Republic of Korea; Sulpiride; Teratogens